Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from EVE Health Group Limited ( (AU:EVE) ) is now available.
EVE Health Group Limited has announced the successful manufacture and distribution of Dyspro™, a cannabinoid-based gummy designed to address dysmenorrhoea and endometriosis, two significant women’s health issues. The product is now available for prescription through TeleDocs’ telehealth network, with additional distribution pathways being explored. This launch marks a pivotal moment for EVE as it aims to meet the substantial unmet medical needs in this market, which is expected to grow significantly in the coming years.
More about EVE Health Group Limited
EVE Health Group (ASX: EVE) is an Australian-based health company focused on developing and commercializing evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract, EVE delivers science-led innovations to support consumer and practitioner health across retail, pharmacy, and clinical channels.
Average Trading Volume: 327,579
Technical Sentiment Signal: Sell
Current Market Cap: A$7.14M
For a thorough assessment of EVE stock, go to TipRanks’ Stock Analysis page.